Investment analysts at HC Wainwright cut their Q2 2025 earnings per share (EPS) estimates for shares of Avadel ...

Ten companies across mixed sectors also mirrored a broader market optimism, booking modest gains during the end of the ...

Equities researchers at HC Wainwright cut their Q1 2025 EPS estimates for shares of Soleno Therapeutics in a report released ...

H.C. Wainwright analyst initiates coverage on Surf Air Mobility Inc. with a Buy rating and $12 price target, citing potential ...

Fintel reports that on March 7, 2025, HC Wainwright & Co. initiated coverage of Surf Air Mobility (NYSE:SRFM) with a Buy ...

H.C. Wainwright lowered the firm’s price target on Repare Therapeutics (RPTX) to $5 from $10 and keeps a Buy rating on the shares following the ...

H.C. Wainwright analyst Amit Dayal initiated coverage of Surf Air Mobility (SRFM) with a Buy rating and $12 price target The firm views Surf ...

Fintel reports that on March 6, 2025, HC Wainwright & Co. initiated coverage of ImmunityBio (NasdaqGS:IBRX) with a Buy ...

Rusfertide could become a blockbuster therapy for polycythemia vera, H.C. Wainwright analyst Douglas Tsao wrote March 4 after the injectable hepcidin mimetic peptide hit its primary endpoint and all ...

Plug Power (Nasdaq: PLUG). From a high north of $3, shares of the hydrogen pioneer have been cut roughly in half, falling as ...

LAVA Therapeutics reviews strategic options amid cost cuts. HC Wainwright downgrades stock, citing uncertainties over LAVA-1266 and possible business shifts.

A live webcast and replay will be available under "Events and Presentations" in the News & Presentations section of the IN8bio website at https://investors.in8bio.com. IN8bio is a clinical-stage ...